VolitionRx Completes $4.6 Million Public Offering

Stradling represented VolitionRx (NYSEA: VNRX), a multi-national epigenetics company, in its $4.6 million public offering of 2,960,000 shares of common stock and accompanying warrants to purchase up to an aggregate of 1,480,000 shares of common stock. The offering included participation from both new and existing investors and provides additional capital to support the company's continued growth and strategic initiatives.